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Host genome studies are increasingly available for the study of infectious disease susceptibility. Current
technologies include large-scale genotyping, genome-wide screens such as transcriptome and silencing (si-
lencing RNA) studies, and increasingly, the possibility to sequence complete genomes. These approaches are
of interest for the study of individuals who remain uninfected despite documented exposure to human im-
munodeficiency virus type 1. The main limitation remains the ascertainment of exposure and establishing
large cohorts of informative individuals. The pattern of enrichment for CCR5 D32 homozygosis should serve
as the standard for assessing the extent to which a given cohort (of white subjects) includes a large proportion
of exposed uninfected individuals.
The discussion on the protective factors that allow a
small number of individuals to avoid infection despite
repeated exposure is increasingly centered on (1) the
nature of the genetic factors that may underlie this trait,
(2) the technical approaches used to identify them, and
(3) the study population and its defining characteristics.
In the present commentary, we discuss these aspects
under the common theme of integrating large-scale
data sets that are mainly but not solely obtained from
genomic studies. The emphasis here is on understand-
ing the importance of study design and defining the
phenotype of human immunodeficiency virus (HIV)
resistance. These are essential aspects for the success of
these studies; in fact, cohort issues, not technological
limits, are increasingly recognized as limiting progress
in the field.
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RESISTANCE TO HIV INFECTION
The identification of the highly protective CCR5 D32
allele demonstrated the importance of genetic factors
in determining susceptibility to HIV in white subjects.
However, no similar factor has been identified in other
populations despite extensive evidence for similar traits
of resistance to HIV. The research community has ad-
dressed this specific question through a candidate gene
approach (data compiled at the HIV-Pharmacogenom-
ics Web site [1]). The study populations have generally
included exposed uninfected individuals, mother-child
pairs, or infected individuals and the uninfected general
population, to compare allelic frequencies. The pro-
posed variants thus studied have been supported by
unequal evidence. Variants or haplotypes of CCL5,
CCL2-CCL7-CCL11, CCL3, and DEFB1 have been as-
sociated with differential susceptibility to infection or
transmission in 11 study. There is controversy regarding
the role of variants of KIR, CXCR1, DARC, CCL3L1,
CXCL12, CD209, CLEC4M, MBL2, and ABCB1 in sus-
ceptibility to infection. There is insufficient evidence or
lack of confirmation concerning a role for variants of
IL10, IL18, IRF1, IL4R, PTPRC, and APOBEC3B. It is
clear that identifying genetic factors underlying resis-
tance requires a large well-defined study population
with a clear phenotype (see below), and the unbiased
identification of candidate regions using novel tech-
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Figure 1. Summary diagram of the genome pipeline. Genome-wide
association studies (GWASs) are now processive techniques that have
been applied to the analysis of 110,000 individuals infected with human
immunodeficiency virus. The individual studies can be pooled through
meta-analysis to identify additional genetic variants. Sequencing of the
complete human genome or the coding genome (exome) are new steps
being applied to a limited number of individuals considered highly in-
formative (eg, elite controllers, rapid progressors, exposed uninfected
individuals), with the goal of identifying rare mutations. Other genome-
wide screens, such as transcriptome or silencing RNA analyses, may
contribute to lists of candidate genes that may be prioritized for se-
quencing. All approaches will generally lead to in-depth targeted rese-
quencing in more individuals. WG, whole-genome.
nologies that provide information on likely mechanisms of
protection.
Genome-wide association studies (GWASs) constitute the
first level of assessment of the impact of common genetic var-
iants in complex traits, such as HIV resistance. Common var-
iation is defined as a single-nucleotide polymorphism (SNP)
found in 5% of individuals in a given population. GWASs
have been used to identify variants modulating viral load or
disease progression in individuals who are already HIV positive
[2–7]. These studies are consistent in underscoring the im-
portance of the MHC region at the genome scale and of the
CCR5-CCR2 locus. Overall, the common variants identified to
date explain !15% of the observed variance in viral load or
progression in infected individuals. The unexplained variation
may represent yet undiscovered genetic factors as well as viral
strain or environmental factors.
To identify the factors responsible for the remaining genetic
variation, necessary steps forward include conducting a meta-
analysis of all currently available GWASs, a step that has proved
highly successful in other fields, as in understanding the genetic
structure of diabetes or human height. Here, meta-analyses of
genome-wide SNP data on 1100,000 individuals have yielded
1100 validated genetic loci influencing those traits [8]. Second,
new technology (see below) increasingly allows the interroga-
tion of less common and rare genetic variants (!5% in the
population). Again, the model of diabetes genetics illustrates
the point by describing a scenario in which common and rare
variants may both occur at the same genetic loci yet differ in
their power of the association and effect on the trait. Third,
the frequent call for candidate gene approaches illustrates the
intellectual tension between analyses that are agnostic to the
nature of the genes involved and those guided by current bi-
ological and functional knowledge. The new element that has
animated the debate is the possibility of identifying candidate
genes or pathways by applying advanced technologies that in-
terrogate the complete genome—for example, genome-wide
RNA silencing and transcriptome screens. Figure 1 illustrates
the genomic pipeline that integrates the various approaches.
TECHNICAL APPROACHES TO IDENTIFYING
GENETIC FACTORS
GWAS analysis. Genotyping at the genomic scale generally
implies the assessment of 500 to 1 million SNPs per individual.
The SNPs assessed by the most widely used commercial plat-
forms have been selected to represent common variation in
humans and do not directly interrogate all known variants.
More SNPs are needed when the study population is of African
ancestry. In addition to HIV, GWASs have been completed for
hepatitis C virus [9–12], Mycobacterium leprae infection [13],
and malaria [14]. In all cases, the approach has shed light on
pathogenesis. Of particular relevance to HIV pathogenesis and
resistance, current GWASs are mostly limited to populations
of European ancestry. Generating such data in other popula-
tions, particularly in Africa, has the potential to identify novel
loci. However, such studies involve technical challenges, be-
cause more SNPs need to be genotyped owing to shorter hap-
lotype lengths.
Whole-genome analysis. Current GWASs have been criti-
cized for their inability to interrogate rare variants, and for the
limited amount of genetic variance currently explained. Thus,
there has been growing interest in prioritizing the analysis of
rare mutations that may carry a significant effect for the in-
dividual who carries them and may collectively explain part of
the remaining unexplained variance [8]. Investigators are work-
ing on the various competing possibilities: lowering the cost
for whole-genome sequencing to make its application more
feasible in large samples, concentrating resequencing efforts on
the complete exome of an individual (the 2% sequence in the
genome that is coding) [15], or increasing the density of the
coverage through a process known as imputation [16]. The step
of imputation assigns additional variants to an individual based
on haplotype data from well-characterized external data sets
(HapMap phase 3 or the complete genome sequencing of11000
humans from several populations [17]) that thus do not need
to be directly typed. At a different scale, resequencing is in-
creasingly used in the follow-up of loci identified in GWASs;
for HIV, this is being done across the MHC region.
Transcriptome analysis. Large-scale analysis of expression
patterns are targeting both tissue and cell populations from the
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Figure 2. Considerations affecting the power of variant detection over a range of effect sizes in genetic discovery studies in exposed uninfected
individuals. The power of genetic discovery is a function of sample size, enrichment of the causal variants in the case population, minor allele
frequency in the population, and effect size. Small sample sizes (!500 case subjects) have only modest ability to detect variants with large effects
(odds ratio [OR], 15; eg, HLA-B*5701–tagging single-nucleotide polymorphisms associated with viral control) at a genome-wide discovery threshold
of . Identification of variants with even greater effects, such as CCR5 D32 homozygosity in exposed uninfected individuals (OR, 110)8P ! 5 10
would still require 1100 case subjects and control subjects. These considerations are of particular importance in light of the modest effects (OR, !2)
for validated loci discovered in other complex traits. This power is further reduced by ambiguous phenotype definitions, because the allele frequency
differences between case and control subjects would be reduced.
in vivo HIV setting, as well as cell populations exposed to in
vitro perturbations [18, 19]. Transcriptome analysis is also
shedding light on the dynamics of infection in pathogenic and
nonpathogenic models of SIV infection [20–22]. These analyses
use microarrays covering 120,000 genes and regularly identify
one-third to two-thirds of the genes as being expressed in the
tissue or cell of interest. Against this level of coverage, the new
RNA deep sequencing approaches allow the quantitation of
more rare transcripts, splice isoforms, and small RNAs [23].
RNA deep sequencing also provides sequence variation infor-
mation (eg, SNPs) and is the most powerful approach to the
study of samples that are enriched for transcripts of interest,
in particular those obtained by chromatin immunoprecipita-
tion. On the other side of the scale, a number of technologies
aim at the high-throughput analysis of a limited number of
transcripts (eg, !500), representing signatures of a particular
state or full pathways [24]. As a rule of thumb, deep sequencing
may need 11 mg or 1 million cells; microarray analysis, 1100
ng or 100,000 cells; and next-generation digital gene expression
technology, 10 ng or 10,000 cells. Economy and speed also
decrease with decreases in the number of transcripts targeted.
Expression analysis is increasingly directed to the identification
of micro-RNAs relevant to antiviral defense. Metabolomics and
proteomics are also used in analysis of in vivo and in vitro
response to HIV or other relevant viruses [25].
Silencing-RNA screening. Four types of silencing RNA
(siRNA) screening tests have been used to identify host factors
required for HIV replication in vitro (reviewed in [25] and
[26]). The results have shown some of the limitations of the
technology for generating reproducible lists of candidate genes
for HIV dependency factors. Whereas 1000 genes were iden-
tified by the different screens, only 34 were shared by2 stud-
ies. However, detailed meta-analysis and network analysis of
the data can point to a number of genes and pathways shared
across studies—for example, the nuclear pore machinery, the
mediator complex, a number of key kinases, and components
of the nuclear factor–kB complex—which should be considered
key elements of the cellular machinery supporting viral repli-
cation [26]. It is unknown, however, how these genes, or var-
iations thereof, may relate to in vivo susceptibility to infection.
Resequencing efforts have been initiated by several groups to
answer this question.
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Closing the loop: systems and network biology. Many of
the techniques described above may not generate much more
than descriptive data that in isolation may fail to identify key
genes, pathways, or factors relevant for understanding suscep-
tibility or pathogenesis or for developing vaccines. Systems bi-
ology or network biology has been proposed as the approach
to integrate high-throughput biological data obtained through
clearly designed experiments that include controlled pertur-
bation of the system (eg, exposure of cells to a cytokine), re-
construction of the network and its regulators, silencing of the
candidate genes or master regulators, and biological interro-
gation of the resulting system [27]. In light of the currently
available technologies for interrogating the whole genome, such
analytical approaches hold the most promise for explaining the
biological underpinnings of reduced susceptibility to HIV.
DEFINING CHARACTERISTICS OF
A STUDY POPULATION
The success of the various technologies just described for dem-
onstrating the bases of resistance to HIV infection will depend
heavily on the study design—in particular, the specificity of the
clinical or biological phenotype and the power calculation of
the study. Specifically, the relative contributions of cultural,
viral, host genetic, and (possibly) environmental cofactors will
depend profoundly on the “tightness” of the measurement of
the phenotype.
It is important to consider the enrichment of CCR5 D32
homozygosity in hemophiliac individuals as a model for the
design of studies in exposed uninfected individuals. The fre-
quency of CCR5 D32 homozygosity increases several fold, from
1%–3% in the general white population to frequencies up to
25% in uninfected hemophiliacs, with the highest frequencies
in those with severe hemophilia. This is the benchmark of what
is to be expected from a factor that confers almost absolute
protection in a population with unequivocal repeated exposure
to HIV. Therefore, the identification of factors that do not
confer absolute protection and the study of a population with
poorly defined levels of exposure will be challenging and require
significant statistical power. As demonstrated by Figure 2, the
power to detect variants with decreasing effect size greatly di-
minishes as sample sizes are reduced. Thus, even detection of
variants with large effect sizes relative to those described by
current GWASs (ie, 12) can be achieved only by using large
numbers of subjects (11000 case subjects and 11000 control
subjects) or greatly enriching the study population for indi-
viduals with the most specific phenotype. In practice, both are
advisable to maximize discovery because, even with clear phe-
notypes, polygenic underpinnings and heterogeneity may re-
duce the power to detect individual variants. Studies will need
to make phenotype definition and cohort assembly a priority;
technology will not remediate a poor study design.
Using an alternative approach, researchers who have previ-
ously obtained genome-wide data from HIV-1–infected indi-
viduals will assess whether infected subjects, unlike those who
are exposed but uninfected, are depleted of protective markers.
For example, CCR5 D32 homozygosis is reduced to a frequency
of 1:1000 among individuals included in HIV GWASs. Here,
the comparator is the general population, representing the ref-
erence for genetic variant frequencies. A meta-analysis of
GWASs and reference populations is currently underway.
CONCLUSIONS
Studies of the infected individual suggest that the genetic basis
of human susceptibility to HIV-1 includes common variants,
and probably an undefined number of rarer variants. The iden-
tification of additional common variants will require the com-
pletion of a meta-analysis of GWASs with sufficient power to
identify the less common variants and those with less contri-
bution to the phenotype. From this point on, exploring the
nature of rarer variants will require a shift in technology to
whole-genome or exome sequencing. This is still an unexplored
but promising territory in medicine. For the second general
path, candidate gene analyses will require feeding from other
types of large-scale screens, such as siRNAs and expression
analysis, and from more integrative approaches and systems
biology [25]. For other disorders (eg, metabolic and autoim-
mune diseases), the identification of multiple genetic loci and
markers allows the first attempts at building genetic scores and
proposing interactive models for those diseases.
Investigators studying HIV acquisition cohorts of exposed
uninfected individuals should design a genomics pipeline based
on the progress and shortfalls of the studies already completed
in HIV-infected individuals, paying particular attention to is-
sues of power and phenotype definition. The pattern of en-
richment for CCR5 D32 homozygosis over the expected fre-
quency in the reference population should be used as a reliable
tool to assess the extent to which a given cohort includes a
large proportion of exposed uninfected individuals, although
this estimate can be applied only to white participants.
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